Drug Comparison
For educational purposes only — a decision-support tool, not a substitute for clinical judgment.
Side-by-side rubric across 96 psychiatric medications. Every rating traces to a verbatim primary-source quote — click any cell to see it.
How to read this tool ▾
Rating scale
– Favorable / lower than class baseline
± Minimal / equivocal
+ Low / uncommon
++ Moderate / common
+++ High / very common
++++ Very high / class-outlier
Frequency vs severity
F = frequency, S = severity. Each gets its own pill colored on the same traffic-light scale: green → blue → yellow → orange → red. Click any cell for incidence percentages and NNH.
Evidence tier
A Network meta-analysis / RCT / FDA label
B Cohort / registry / pooled label data
C Expert review / textbook / case series
Sourcing
Click any cell to see the verbatim source quote and citation. Missing data shows n/a.
Data depth
++ Graded — frequency + severity, primary-source traces
+ FDA label — §6 frequency only (dashed border). Click for sub-types.
Blank — not yet checked (not “absent”)
–±++++++++++ABCF = frequency · S = severity · Dashed border = FDA label only · Click cell for details
1 drug selected — Tranylcypromine(click to collapse)
1/4 selected
Tranylcypromine
Parnate
Monoamine Oxidase Inhibitor
FDA-approved indications
- Major depressive disorder — second-line after other antidepressants (adults)
Off-label uses
- Social anxiety disorder
- Panic disorder
- Treatment-resistant anxiety
Half-life2 to 3 hours (but irreversible MAO inhibition)
Decision GuideWhen to pick each / when to consider an alternative
Tranylcypromine
Consider when
- Melancholic or low-energy depression — amphetamine-like cyclopropylamine structure provides activation; counteracts psychomotor retardation
- Weight gain or SD intolerable on phenelzine — least weight gain and sexual dysfunction among non-selective MAOIs
- Rapid MAOI onset desired — faster onset than phenelzine; activating profile noticeable within days
- Shorter washout needed for medication transition — ~1 week washout vs 2 weeks for phenelzine/selegiline
- +1 more
Consider an alternative when
- Tyramine-restricted diet adherence unlikely — boxed hypertensive crisis warning at all doses (unlike selegiline 6 mg/24h patch)
- Insomnia or anxiety predominant — overexcitement >10%, insomnia >30%; activating profile worsens these symptoms
- Cardiovascular disease or uncontrolled hypertension — boxed hypertensive crisis warning; tachycardia and palpitations common
- Diabetic patient on insulin or sulfonylurea — distinctive hypoglycemia warning among MAOIs; altered glucose homeostasis
- +1 more
| Axis | Tranylcypromine MAOI |
|---|---|
| Boxed Warnings | |
Suicidality (boxed warning) | |
Mania / hypomania induction | |
Hypertensive crisis (tyramine/MAOI) | |
| CNS | |
Sedation / somnolence | |
Activation / insomnia | |
Seizure risk | |
| Metabolic | |
Weight gain | |
Metabolic (glucose / lipids) | |
| Autonomic | |
Anticholinergic burden | |
Orthostatic hypotension | |
Sweating | |
| Cardiac | |
Blood pressure elevation | |
Heart rate / tachycardia | |
| GI | |
Nausea / GI (general) | |
| Hepatic | |
Liver enzymes / hepatotoxicity | |
| Electrolytes | |
Hyponatremia / SIADH | |
| Sexual | |
Sexual dysfunction | |
| Discontinuation | |
Withdrawal / discontinuation | |
| Interactions | |
Serotonin syndrome risk | |
CYP interactions / DDI profile | |
| Safety | |
Overdose toxicity | |
| Pregnancy | |
Lactation / breastfeeding safety | |
| Drug-specific / distinctive axes | |
Blood dyscrasias only in Tranylcypromine | |